AZD-2693

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameAZD-2693
Drug Alias NameAZD-2693IONIS-AZ6-2.5-LRxION-839
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of Action1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 inhibitors
Targets1-acylglycerol-3-phosphate O-acyltransferase PNPLA3
Therapy Area/IndicationsMetabolic DiseasesLiver CirrhosisHepatic Insufficiency +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesVietnamSingapore +[23] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca AbAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesAstrazeneca Plc
Active IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsMetabolic DiseasesHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A